Novavax Stock News

Beset by delays, this vaccine is becoming available when low-income countries are desperately short of doses.

J.P. Morgan Stick to Their Hold Rating for Novavax

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Novavax, Inc. (Novavax or the Company) (NASDAQ: NVAX) securities between March 2, 2021 and October 19, 2021, inclusive (the Class Period). Novavax investors have until January 11, 2022 to file a lead plaintiff motion. If you suffered a loss on your Novavax inves

Lead Plaintiff Deadline Is January 11, 2022 Lead Plaintiff Deadline Is January 11, 2022

The European Medicines Agency (EMA) has begun evaluating an application for conditional marketing authorization for Novavax Inc''s (NASDAQ: NVAX ) COVID-19 vaccine. The protein-based vaccine candidate will be marketed in the European Union under the brand name Nuvaxovid. Separately, Novavax and Serum Institute of India Pvt. Ltd (SII) announced that the Philippine Full story available on Benzinga.com

LOS ANGELES--(BUSINESS WIRE)---- $NVAX #NVAX--SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Novavax, Inc.

Today, shares of NVAX stock are taking off following a couple of key regulatory updates from the company from two core markets.

LOS ANGELES--(BUSINESS WIRE)---- $NVAX #investors--The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Novavax, Inc. (NVAX) Investors

The EU''s drugs agency EMA has started evaluating an application for conditional marketing authorisation for US biotech firm Novavaxs COVID-19 vaccine, Nuvaxovid. If granted, this will be the fifth vaccine authorised in the European Union.

If approved, it would be the fifth Covid jab authorised for use within the EU.

LONDON - The European Union''s drug regulator said it received an application from Novavax to authorize the American biotechnology company''s coronavirus vaccine, a request that

NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against of Novavax, Inc. (Novavax or the Company) (NASDAQ: NVAX) in the United States District Court for the District of Maryland on behalf of those who purchased Novavax common stock between March 2, 2021 and October 19, 2021, inclusive (the Class Period).

SAN DIEGO, Nov. 15, 2021 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Novavax, Inc. (NASDAQ: NVAX) securities between March 2, 2021 and October 19, 2021, inclusive (the "Class Period") have until January 11, 2022 to seek appointment as lead plaintiff in

SAN FRANCISCO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Novavax, Inc. (NASDAQ: NVAX) investors with significant losses to submit your losses now .